

Figure 1. A mutated form of MCP-1 (7ND) is secreted from cells infected with Ad7ND. COS cells were infected either with Ad7ND or with AdLacZ at the indicated MOI. After 48 hours, the culture media were subjected to sodium dodecyl sulfate-polyacrylamide gel electrophoresis (12%) and analyzed by Western blotting by using antibodies against either (A) FLAG or (B) human MCP-1. Molecular markers are in kilodaltons.

Statistical Analysis

Statistical analysis was performed by 1-way analysis of variance followed by Scheffé's test. $P < .05$ was considered significant.

Results

A Mutant Monocyte Chemoattractant Protein 1, 7ND, Was Secreted From Ad7ND-Infected Cells and Detected in the Serum and Liver of Ad7ND-Infected Rats


In the culture medium from Ad7ND-infected COS cells, 7ND was readily detectable in an MOI-dependent manner, as assessed by Western blotting analysis (Figure 1). Human 7ND and endogenous rat MCP-1 proteins were measured in sera (Figure 2A) and liver

extracts (Figure 2B) from rats infected with Ad7ND. Seven days after gene transfer, a 3-week DMN treatment was begun. It is interesting to note that the amount of rat MCP-1 was not significantly changed by DMN treatment in either serum or liver. 7ND reached a peak on the seventh day after gene transfer and then declined gradually; however, the values were much higher than those obtained for rat MCP-1 in most time periods under DMN injury.

Dimethylnitrosamine-Induced Infiltration by Macrophages and Lymphocytes and Activation of Hepatic Stellate Cells Were Both Suppressed in Ad7ND-Treated Livers

Rats were infused via the tail vein with either saline or an adenovirus expressing 1 of the following:

A (serum)



B (liver)




Figure 2. Amounts of human 7ND and rat MCP-1 in the sera (A) and livers (B) of DMN-injured rats. Rats were given a single infusion of Ad7ND (or saline infusion) via the tail vein. Seven days later, rats were subjected to a 3-week DMN treatment (shown as arrows). Rats were killed 5, 7 (just before the initiation of DMN treatment), 14, 21, and 28 days after Ad7ND injection. Means \pm SD ($n = 4$) are shown.




Figure 3. Infiltration of macrophages and lymphocytes into DMN-treated livers. Rats were given a single infusion of saline, AdLacZ, Ad7ND, or AdTβ-TR via the tail vein. Seven days later, some rats were administered DMN once (shown as *with DMN*) and some rats were not administered DMN (shown as *without DMN*; histology not shown). Twenty-four hours after the DMN challenge, they were killed, and liver sections were histologically examined either by immunohistostaining against CD68, to detect macrophages (A), or by hematoxylin staining for lymphocytes (not shown; original magnification, 200X). Similar histology was seen in all 4 rats in each group. The numbers of (B) macrophages and (C) lymphocytes were semiquantitated (see Materials and Methods). Four fields in each of 4 rats (a total of 16 fields in each group) were examined, and the number of cells per high-power field is shown as mean ± SD. n.s., statistically not significant. Rats never treated with adenovirus or DMN were also analyzed (shown as *intact*).

β-galactosidase (AdLacZ), a truncated TGF-β receptor (AdTβ-TR), or a mutated MCP-1 (Ad7ND). Seven days later (when the expression of the introduced molecules had reached a submaximal level), DMN was given. One day after a single injection of DMN, we analyzed liver sections by hematoxylin staining and immunohistostaining against CD68, which is a specific marker for macrophages. Macrophages were detectable in the centrilobular area of the livers of AdLacZ-infected, AdTβ-TR-infected, or saline-injected rats: there were no differences among these 3 groups. However, macrophages were greatly reduced in Ad7ND-treated livers (Figure 3A).

The numbers of CD68-positive cells (per high-power field) were 29 ± 3.5 in saline-treated livers, 27.5 ± 2.1 in AdLacZ-treated livers, 27.5 ± 11.4 in AdTβ-TR-treated livers, and only 7.1 ± 1.2 in Ad7ND-treated livers (Figure 3B). Similarly, the numbers of lymphocytes (histology not shown) were 98 ± 7.5 in saline-treated livers, 101 ± 2.5 in AdLacZ-treated livers, 93 ± 5.5 in AdTβ-TR-treated livers, and only 40 ± 3.5 per high-power field in Ad7ND-treated livers (Figure 3C). Without DMN treatment, neither macrophages nor lymphocytes (histology not shown) were increased in the livers of AdLacZ-infected, AdTβ-TR-infected, and




Figure 4. α -Actin-positive cells in DMN-treated livers. Rats were treated with either an adenovirus or saline as described in the legend to Figure 3 and then subjected to DMN for 3 consecutive days. One day after the last DMN injection (the fourth day), livers were examined by immunohistostaining against α -actin (original magnification, 200 \times). Rats never treated with adenovirus or DMN were also analyzed (shown as *intact*). Similar histology was seen in all 4 rats in each group.

Ad7ND-infected livers compared with intact livers (subjected to no injection of either saline or adenovirus and no DMN treatment; Figure 3B and C).

Next, after a 3-day DMN treatment, we examined livers for α -actin-positive cells (a marker of activated HSC). They were readily detectable, not only in AdLacZ- or saline-treated, but also in AdT β -TR-treated livers. In contrast, we could see none in the Ad7ND-treated livers (Figure 4).

Inhibition of Macrophage Infiltration or of Transforming Growth Factor β Signaling Markedly Suppresses Liver Fibrogenesis and Preserves Liver Function

After a 3-week DMN treatment, the hydroxyproline content of livers was measured as a quantitative evaluation of fibrosis (Figure 5). The hydroxyproline contents in the livers of both AdLacZ- and saline-treated rats were approximately 3-fold higher than in intact livers, as previously observed.¹⁰⁻¹² In contrast, in the Ad7ND-treated and AdT β -TR-treated livers, the hydroxyproline content remained close to the level seen in intact livers.

After the DMN treatment, the serum levels of aspartate aminotransferase, alanine aminotransferase, and total bilirubin were all increased, and both the body and liver weights were decreased, probably because of liver dysfunction. However, these values were preserved or better

maintained in the Ad7ND-treated or AdT β -TR-treated groups (Table 1).

After a 3-week DMN treatment, we analyzed liver histology both by Masson trichrome staining and by immunohistostaining against α -actin. In accordance with the data on hydroxyproline content (Figure 5), both Ad7ND-treated and AdT β -TR-treated livers showed a fibrotic area that was markedly smaller than that seen in




Figure 5. Hydroxyproline content of DMN-treated livers. Rats were treated with either adenovirus or saline as described in the legend to Figure 3 and then subjected to a 3-week DMN treatment. Hydroxyproline content of livers is shown as mean \pm SD. Three samples from each of 4 rats were analyzed for each group. n.s., statistically not significant. Rats never treated with adenovirus or DMN were also analyzed (shown as *intact*).

Table 1. Serum Hepatobiliary Parameters and Body and Liver Weights

Variable	Total bilirubin (mg/mL)	AST (IU/mL)	ALT (IU/mL)	Body weight (g)	Liver weight (g)
Intact	0.2 ± 0.1	68 ± 16	40 ± 9	350 ± 20	3.5 ± 0.1
AdLacZ	0.2 ± 0.1	71 ± 11	39 ± 7	340 ± 20	3.6 ± 0.1
Saline + DMN	0.7 ± 0.6	495 ± 103	245 ± 88	290 ± 20	2.4 ± 0.4
AdLacZ + DMN	0.8 ± 0.7	525 ± 149	232 ± 97	290 ± 30	2.3 ± 0.5
Ad7ND + DMN	0.3 ± 0.1 ^a	134 ± 16 ^a	69 ± 7 ^a	350 ± 10 ^a	3.4 ± 0.1 ^a
AdTβ - TR + DMN	0.4 ± 0.1 ^a	222 ± 84 ^a	69 ± 25 ^a	350 ± 10 ^a	3.5 ± 0.1 ^a

NOTE. Rats were given a single infusion of saline, AdLacZ, Ad7ND, or AdTβ-TR via the tail vein. Seven days later, a 3-week DMN treatment was given to some rats (shown as +DMN). After a 3-week DMN treatment, blood was collected, and body and liver weights were measured. Serum total bilirubin, AST, and ALT and body and liver weights are shown as mean ± SE (n = 4). Rats never subjected to adenovirus infection or treated with DMN were also measured (shown as Intact).

AST, aspartate aminotransferase; ALT, alanine aminotransferase.

^aP < .05 vs. AdLacZ + DMN.

the AdLacZ- and saline-injected rats, and α-actin-positive cells were almost undetectable (Figure 6).

In the AdTβ-TR-treated livers, α-actin-positive cells were readily detectable after the initial 3-day DMN treatment (Figure 4). We assumed that activated HSC disappeared through apoptosis under conditions in which the action of TGF-β was suppressed. We therefore performed TUNEL staining on the fourth day after starting DMN treatment. TUNEL-positive cells were increased in the AdTβ-TR-treated livers; however, no such apoptotic cells were observed in the AdLacZ- or saline-injected livers (Figure 7A). Immunohistostaining against α-actin confirmed that the TUNEL-positive cells in the AdTβ-TR-treated livers (Figure 7A) were indeed α-actin positive (Figure 7B).

Discussion

Inflammation induces infiltration by leukocytes and monocytes/macrophages into inflamed tissues.¹ Tis-

sue remodeling or fibrosis then follows the inflammation. MCP-1, one of the CC chemokines, attracts monocytes/macrophages bearing CCR2.¹⁻³ In this study, the roles of such macrophages in injury-induced liver fibrogenesis were investigated by overexpressing a mutated MCP-1 (7ND), which is reported to suppress the actions of MCP-1.^{15,23-25} In the Ad7ND-treated rats, DMN-induced infiltration by macrophages and lymphocytes into injured livers was markedly suppressed (Figure 3), the activation of HSC was eliminated (Figure 4), and liver fibrogenesis was greatly prevented (Figures 5 and 6). The cellular infiltration and activation of HSC observed immediately after infliction of the injury were similar between the AdTβ-TR-treated livers and the controls (saline-infused or AdLacZ-infected rats; Figures 3 and 4). Our study shows that infiltrated macrophages are critical for HSC activation and subsequent fibrogenesis and, importantly, that TGF-β is not an activating factor for HSC. It is suggested that the infiltrated macrophages




Figure 6. Histology of livers after a 3-week DMN treatment. Rats were treated as described in the legend to Figure 5. Liver sections were histologically examined with the aid of Masson trichrome staining (MT) or by immunohistostaining against α-actin (original magnification, 100×). Similar histology was seen in all 4 rats in each group.




Figure 7. Apoptosis of activated HSC. Rats were injected with saline, AdLacZ, or AdT β -TR and then treated with DMN on 3 consecutive days. On the fourth day after starting DMN treatment, liver sections were histologically examined by TUNEL staining (A) (original magnification, 200 \times). Livers from AdT β -TR injection were examined by double staining (TUNEL staining and immunohistostaining against α -actin; see Materials and Methods) (B) (original magnification, 400 \times). TUNEL-positive cells are indicated by arrows. Similar histology was seen in all 4 rats in each group.

may themselves secrete an activating factor or factors for HSC.

We have previously shown that anti-TGF- β intervention inhibits liver fibrogenesis^{11,13} and its progression.¹² In this study, we found that suppression of infiltration by macrophages and lymphocytes through overexpression of 7ND led to a powerful suppression of liver fibrogenesis to a similar degree as blockade of TGF- β but that the underlying mechanisms seem to be different. Activation of HSC in the initial stage immediately after injury was already eliminated in the Ad7ND-treated livers (Figure 4). Probably because HSC activation was inhibited, the subsequent progress toward fibrosis was suppressed in the Ad7ND-treated livers, thus supporting the idea that activation of HSC is the initial and critical event that leads to liver fibrosis. It has been considered for a long time that TGF- β is the HSC-activating factor (or at least one of the activating factors).¹¹ However, our study clearly shows for the first time that TGF- β is not the HSC-activating factor, because a substantial number of activated HSC were present in the AdT β -TR-treated livers (Figure 4); indeed, the numbers of activated HSC were the same among saline-treated, AdLacZ-treated, and AdT β -TR-treated livers. We confirmed previously

that virtually all liver cells are infected with an adenovirus when one is administered to rats with intact livers,^{11,13} so the possibility can be excluded that all of these activated HSC were uninfected with AdT β -TR. Although substantial numbers of activated HSC were seen after a 3-day DMN treatment, most disappeared during the next 2 weeks of DMN treatment (Figure 6). The activated HSC are probably eliminated through apoptosis under conditions in which TGF- β signaling is inhibited. Indeed, we showed that in the AdT β -TR-treated livers, but not in the AdLacZ- or saline-injected ones, activated HSC were in apoptosis (Figure 7). Saile et al²⁶ reported that HSC undergo CD95-mediated spontaneous apoptosis when they are activated, and TGF- β inhibits CD95-agonistic antibody-induced apoptosis of activated HSC in culture.²⁷ On the basis of these reported findings and our present study, it is likely that TGF- β is required for the activated HSC to survive. Consequently, fibrogenesis was markedly inhibited in the AdT β -TR-treated livers despite activation of HSC in the initial stage after injury. To judge from our findings, anti-TGF- β intervention ought to be superior to anti-MCP-1 therapy for treating liver cirrhosis patients, most of whom already

have some degree of fibrosis or injury. This issue is now under further investigation in our laboratory.

Marra et al²⁸ reported that MCP-1 enhances the migration of HSC in culture. Moreover, it has been reported that HSC themselves produce MCP-1^{29,30} and that TGF- β induces the secretion of MCP-1.²⁹ Together with our present study, it is likely that MCP-1 stimulates liver fibrogenesis by 2 mechanisms: (1) MCP-1 induces macrophage infiltration, and macrophages secrete an activating factor(s) for HSC; (2) MCP-1 acts directly on activated HSC to modulate their function. In favor of this notion, it has been reported that in cultured skin fibroblasts, MCP-1 increases the gene expressions of α_1 (I) procollagen and TGF- β ³¹ and of matrix metalloproteinase 1 and 2 (and of their inhibitor, tissue inhibitor of metalloproteinase 1)³² and that MCP-1 stimulates the proliferation of cultured vascular smooth muscle cells.³³ Collectively, these observations suggest that MCP-1 secreted from macrophages and from HSC themselves may facilitate the production of TGF- β , as well as of matrix metalloproteinases and their inhibitors, thereby enhancing inflammation and tissue remodeling (fibrogenesis).

We expressed 7ND in livers expecting that it would inhibit MCP-1 as a dominant-negative mutant.¹⁶ It has been reported that a 75:1 molar ratio of 7ND/wild-type MCP-1 is needed for a 50% inhibition of monocyte chemotaxis in vitro.¹⁶ In our setting, the amount of 7ND was substantially higher than that of rat MCP-1 in both sera and livers for at least 2–2.5 weeks under DMN treatment (Figure 2). We have not yet determined how much 7ND is required to inhibit the actions of MCP-1 in vivo, specifically in the case of the DMN-injured rat liver. Thus, it is not certain whether the actions of MCP-1 were indeed inhibited in our experiments or whether the observed inhibition of macrophage infiltration was indeed achieved via a suppression of MCP-1 by 7ND. We would like to add that numerous reports (13, to our knowledge) have been published in which the same 7ND construct as that used in this study was introduced (either by direct injection or by electroporation with an expression plasmid) into various animal models, and suppression of macrophage infiltration and some biological effects were seen in every one of these reports. In 3 of these 13 studies, both 7ND and endogenous MCP-1 proteins in serum were measured, and the values obtained (7ND/MCP-1) were 220/71 pg/mL,²³ 226/85 pg/mL,²¹ and 124/92 pg/mL²⁵ (all in mice). We detected a peak value of 528 ± 182 pg/mL for 7ND and 62 ± 12 pg/mL for endogenous rat MCP-1. Both this peak value for 7ND and the ratio between 7ND and endogenous MCP-1 are the highest among the values reported in the literature so far.

In summary, we have shown that the macrophages that infiltrate into livers immediately after an initial injury are critical both for HSC activation and for the subsequent fibrogenesis, and we also showed that TGF- β , which is required for activated HSC to survive, is not an activating factor for HSC (at least in this situation). Macrophages may themselves secrete an activating factor(s) for HSC.

References

- Luster AD. Chemokines—chemotactic cytokines that mediate inflammation. *N Engl J Med* 1998;338:436–445.
- Rollins BJ. Chemokines. *Blood* 1997;90:909–928.
- Baggiolini M. Chemokines and leukocyte traffic. *Nature* 1998;392:565–568.
- Czaja MJ, Geerts A, Xu J, Schmiedeborg P, Ju Y. Monocyte chemoattractant protein 1 (MCP-1) expression occurs in toxic rat liver injury and human liver disease. *J Leukoc Biol* 1994;55:120–126.
- Yamaguchi Y, Matsumura F, Takeya M, Ichiguchi O, Kuratsu JI, Horiuchi T, Akizuki E, Matsuda T, Okabe K, Ohshiro H, Liang J, Mori K, Yamada S, Takahashi K, Ogawa M. Monocyte chemoattractant protein-1 enhances expression of intercellular adhesion molecule-1 following ischemia-reperfusion of the liver in rats. *Hepatology* 1998;27:727–734.
- Marra F, DeFranco R, Grappone C, Milani S, Pastacaldi S, Pinzani M, Romanelli RG, Laffi G, Gentilini P. Increased expression of monocyte chemoattractant protein-1 during active hepatic fibrogenesis: correlation with monocyte infiltration. *Am J Pathol* 1998;152:423–430.
- Fisher NC, Neil DA, Williams A, Adams DH. Serum concentrations and peripheral secretion of the beta chemokines monocyte chemoattractant protein 1 and macrophage inflammatory protein 1alpha in alcoholic liver disease. *Gut* 1999;45:416–420.
- Ramadori G, Saile B. Mesenchymal cells in the liver—one cell type or two? *Liver* 2002;22:283–294.
- Friedman SL. Seminars in medicine of the Beth Israel Hospital, Boston. The cellular basis of hepatic fibrosis. Mechanisms and treatment strategies. *N Engl J Med* 1993;328:1828–1835.
- Yamamoto H, Ueno H, Ooshima A, Takeshita A. Adenovirus-mediated transfer of a truncated transforming growth factor- β (TGF- β) type II receptor completely and specifically abolishes diverse signaling by TGF- β in vascular wall cells in primary culture. *J Biol Chem* 1996;271:16253–16259.
- Qi Z, Atsuchi N, Ooshima A, Takeshita A, Ueno H. Blockade of TGF- β signaling prevents liver fibrosis and dysfunction in the rat. *Proc Natl Acad Sci U S A* 1999;96:2345–2349.
- Nakamura T, Sakata R, Ueno T, Sata M, Ueno H. Inhibition of transforming growth factor β prevents progression of liver fibrosis and enhances hepatocyte regeneration in dimethylnitrosamine-treated rats. *Hepatology* 2000;32:247–255.
- Ueno H, Sakamoto T, Nakamura T, Qi Z, Atsuchi N, Takeshita A, Shimizu K, Ohashi H. A soluble transforming growth factor β receptor expressed in muscle prevents liver fibrogenesis and dysfunction in rats. *Hum Gene Ther* 2000;11:33–42.
- Reeves HL, Friedman SL. Activation of hepatic stellate cells—a key issue in liver fibrosis. *Front Biosci* 2002;7:d808–d826.
- Zhang Y, Rutledge BJ, Rollins BJ. Structure/activity analysis of human monocyte chemoattractant protein-1 (MCP-1) by mutagenesis. Identification of a mutated protein that inhibits MCP-1-mediated monocyte chemotaxis. *J Biol Chem* 1994;269:15918–15924.

16. Zhang Y, Rollins BJ. A dominant negative inhibitor indicates that monocyte chemoattractant protein 1 functions as a dimer. *Mol Cell Biol* 1995;15:4851-4855.
17. Jenkins SA, Grandison A, Baxter JN, Day DW, Taylor I, Shields R. A dimethylnitrosamine-induced model of cirrhosis and portal hypertension in the rat. *J Hepatol* 1985;1:489-499.
18. Jezequel AM, Mancini R, Rinaldesi ML, Macarri G, Venturini C, Orlandi F. A morphological study of the early stages of hepatic fibrosis induced by low doses of dimethylnitrosamine in the rat. *J Hepatol* 1987;5:174-181.
19. Ueno H, Li JJ, Tomita H, Yamamoto H, Pan Y, Kanegae Y, Saito I, Takeshita A. Quantitative analysis of repeat adenovirus-mediated gene transfer into injured canine femoral arteries. *Arterioscler Thromb Vasc Biol* 1995;15:2246-2253.
20. Niwa H, Yamamura K, Miyazaki J. Efficient selection for high-expression transfectants with a novel eukaryotic vector. *Gene* 1991;108:193-199.
21. Miyake S, Makimura M, Kanegae Y, Harada S, Sato Y, Takamori K, Tokuda C, Saito I. Efficient generation of recombinant adenoviruses using adenovirus DNA-terminal protein complex and a cosmid bearing the full-length virus genome. *Proc Natl Acad Sci U S A* 1996;93:1320-1324.
22. Woessner JFJ. The determination of hydroxyproline in tissue and protein samples containing small amounts of the amino acid. *Arch Biochem Biophys* 1961;93:440-447.
23. Egashira K, Zhao Q, Kataoka C, Ohtani K, Usui M, Charo IF, Nishida K, Inoue S, Katoh M, Ichiki T, Takeshita A. Importance of monocyte chemoattractant protein-1 pathway in neointimal hyperplasia after periarterial injury in mice and monkeys. *Circ Res* 2002;90:1167-1172.
24. Inoue S, Egashira K, Ni W, Kitamoto S, Usui M, Otani K, Ishibashi M, Hiasa K, Nishida K, Takeshita A. Anti-monocyte chemoattractant protein-1 gene therapy limits progression and destabilization of established atherosclerosis in apolipoprotein E-knockout mice. *Circulation* 2002;106:2700-2706.
25. Ni W, Kitamoto S, Ishibashi M, Usui M, Inoue S, Hiasa K, Zhao Q, Nishida K, Takeshita A, Egashira K. Monocyte chemoattractant protein-1 is an essential inflammatory mediator in angiotensin II-induced progression of established atherosclerosis in hypercholesterolemic mice. *Arterioscler Thromb Vasc Biol* 2004;24:534-539.
26. Saile B, Knittel T, Matthes N, Schott P, Ramadori G. CD95/CD95L-mediated apoptosis of the hepatic stellate cell. A mechanism terminating uncontrolled hepatic stellate cell proliferation during hepatic tissue repair. *Am J Pathol* 1997;151:1265-1272.
27. Saile B, Matthes N, Knittel T, Ramadori G. Transforming growth factor beta and tumor necrosis factor alpha inhibit both apoptosis and proliferation of activated rat hepatic stellate cells. *Hepatology* 1999;30:196-202.
28. Marra F, Romanelli RG, Giannini C, Failli P, Pastacaldi S, Arrighi MC, Pinzani M, Laffi G, Montalto P, Gentilini P. Monocyte chemoattractant protein-1 as a chemoattractant for human hepatic stellate cells. *Hepatology* 1999;29:140-148.
29. Xu Y, Rojkind M, Czaja MJ. Regulation of monocyte chemoattractant protein 1 by cytokines and oxygen free radicals in rat hepatic fat-storing cells. *Gastroenterology* 1996;110:1870-1877.
30. Marra F, Valente AJ, Pinzani M, Abboud HE. Cultured human liver fat-storing cells produce monocyte chemotactic protein-1. Regulation by proinflammatory cytokines. *J Clin Invest* 1993;92:1674-1680.
31. Gharaee-Kermani M, Denholm EM, Phan SH. Costimulation of fibroblast collagen and transforming growth factor beta1 gene expression by monocyte chemoattractant protein-1 via specific receptors. *J Biol Chem* 1996;271:17779-17784.
32. Yamamoto T, Eckes B, Mauch C, Hartmann K, Krieg T. Monocyte chemoattractant protein-1 enhances gene expression and synthesis of matrix metalloproteinase-1 in human fibroblasts by an autocrine IL-1 alpha loop. *J Immunol* 2000;164:6174-6179.
33. Selzman CH, Miller SA, Zimmerman MA, Gamboni-Robertson F, Harken AH, Banerjee A. Monocyte chemotactic protein-1 directly induces human vascular smooth muscle proliferation. *Am J Physiol Heart Circ Physiol* 2002;283:H1455-H1461.

Received June 23, 2003. Accepted September 30, 2004.

Address requests for reprints to: Hikaru Ueno, MD, PhD, Department of Biochemistry and Molecular Pathophysiology, University of Occupational and Environmental Health, School of Medicine, Iseigaoka 1-1, Yahatanishi-ku, Kitakyushu, 807-8555, Japan. e-mail: hueno@med.uoeh-u.ac.jp; fax: (81) 93-692-2777.

Supported by a Grant-in-Aid for Scientific Research from the Ministry of Education, Science and Culture of Japan and by grants from the Takeda Medical Research Foundation (Osaka, Japan), the Sankyo Life Science Foundation (Tokyo, Japan), the Ono Medical Foundation (Osaka, Japan), and the Uehara Memorial Foundation (Tokyo, Japan).

Review

Antiviral therapy for chronic hepatitis C: past, present, and future

NORIO HAYASHI and TETSUO TAKEHARA

Department of Gastroenterology and Hepatology, Osaka University Graduate School of Medicine, 2-2 Yamada-oka, Suita 565-0871, Japan

Antiviral therapy for chronic hepatitis C has dramatically advanced since the discovery of the hepatitis C virus (HCV) in 1989 and the introduction of interferon (IFN) monotherapy in the early 1990s. The current standard therapy uses a combination of pegylated IFN and ribavirin. The duration of therapy and response to therapy are HCV genotype-specific. Genotype 1 patients require 48 weeks of the combination therapy for 50% successful viral elimination, while genotype 2 patients require 24 weeks of therapy for 80% or 90% viral elimination. Early viral kinetics after the initiation of therapy is a useful predictor of the sustained virologic response (SVR), which is formally determined at 24 weeks after completion of the treatment. For example, an early virologic response, which is determined by a 2-log reduction of HCV RNA or viral elimination at 12 weeks after the initiation of therapy, is a strong negative predictor of SVR in genotype 1 patients. In contrast, a rapid virologic response of HCV RNA-negative at 4 weeks after the initiation of therapy identifies genotype 2 "super-responders," who may require a shorter period of therapy. Adherence to therapy is one of the most important factors for successful viral clearance. Hematopoietic growth factors such as epoetin and granulocyte-colony stimulating factor help reduce therapy-mediated cytopenia and improve patient compliance, thereby leading to better viral clearance. New types of anti-HCV agents such as HCV protease and polymerase inhibitors are needed for those patients that do not respond to combination therapy.

Introduction

In 1989, the hepatitis C virus (HCV) was discovered in the United States to be the causative agent of

posttransfusion non-A, non-B hepatitis by Chiron Corporation (Emeryville, CA, USA).¹ By this discovery, HCV was revealed to be the cause of many hepatic diseases of previously unknown origin. HCV is closely associated with hepatocellular carcinogenesis and death due to chronic liver disease. Epidemiologically speaking, it is estimated that 1.7 million people in Japan and 170 million people worldwide are infected with HCV.² Many cases are asymptomatic and result in overt hepatic disease, manifested as hepatic cirrhosis or cancer, only following 20 to 30 years of persistent infection. Thus, HCV infection is of significant concern in terms of public health.

Spontaneous elimination of HCV occurs in approximately 30% of HCV-infected patients within 6 months after infection. However, after this period of time, viral elimination is very rare, with an annual rate of only about 0.2%. Persistent inflammation associated with HCV causes hepatic fibrosis, and as the stage of fibrosis progresses, the risk of cancer increases; annual rates of hepatocarcinogenesis are 0.5% for patients with modest fibrosis and 8% for those with liver cirrhosis.

HCV-associated, progressive hepatic disease can be directly inhibited by interferon (IFN), which is currently the only drug that can eradicate HCV. This review traces the progress of IFN-based therapy for hepatitis C since its introduction and provides a brief overview of the future of HCV treatment.

Introduction of IFN therapy

IFN therapy for hepatitis C dates from 1986, when Hoofnagle et al.³ reported the normalization of serum alanine aminotransferase (ALT) levels following administration of recombinant human IFN α to patients with non-A, non-B hepatitis. In other words, IFN was shown to be biochemically effective as an anti-inflammatory agent before the discovery of HCV.^{4,5}

Received: November 29, 2005 / Accepted: November 30, 2005
Reprint requests to: N. Hayashi




Fig. 1. Milestones of interferon (IFN)-based therapy for chronic hepatitis C. Progress in sustained viral clearance for a difficult to treat patient group, with genotype 1 and a high viral load, from the early 1990s. SVR, sustained virologic response; PegIFN, pegylated interferon

Later, the introduction of a virus identification method using a polymerase chain reaction (PCR) assay revealed cases in which patients became HCV-PCR negative following IFN administration.⁶ The normalization of serum ALT levels is associated with viral eradication, with the exception of a few cases. The discovery of these biochemical and virological effects prompted approval of clinical use of IFN against hepatitis C in the United States in 1991 and in Japan in 1992.

The therapeutic responses to IFN can be classified as sustained virologic response (SVR), relapse, or nonresponse. SVR means complete elimination of HCV, which is defined as the loss of detectable HCV RNA during therapy and its continued absence for at least 6 months after the termination of therapy. Relapse is defined as being HCV-negative at the end of IFN treatment but HCV-positive within 6 months after the termination of therapy. Nonresponse is defined as the absence of a HCV-negative condition even with IFN administration. Initial studies showed that after 6 months of 6MU IFN administration to patients with chronic hepatitis C, SVR, relapse, and nonresponse were each observed in one-third of the patients. Subsequent studies revealed that the antiviral effect is determined mainly by viral factors, namely the viral load and the viral genotype.^{7,8} Genotypes 1a and 1b are more resistant to IFN therapy than genotypes 2a and 2b, and patients with a high viral load are less likely to respond to IFN than those with a lower viral load. A subgroup analysis of patients treated with IFN monotherapy

showed that the SVR rate in genotype 1 patients with a high viral load, accounting for approximately 60% of patients with hepatitis C in Japan, was only 5%. How to improve the therapeutic effect in these patients is the greatest problem for future research and development of IFN therapy (Fig. 1).

Progress of IFN-based therapy

For such resistant cases (patients with genotype 1 and high viral load), extended administration to optimize the total dose of IFN, the introduction of pegylated IFN (PEG-IFN) and coadministration with ribavirin have been used to substantially improve treatment over the past 10 years.

Optimization of the total dose of IFN: extended administration

Two means of increasing the total dose of IFN in resistant cases have been investigated: increasing the dose and extending the administration period. In Japan, patients had usually been given 6MU IFN three times a week for 6 months. Higher doses did not correlate with an increased SVR rate, partly because of the increased incidence of adverse effects and reduced patient compliance. However, extending the administration period proved effective for raising the SVR rate. Kasahara et al.⁹ showed that 12 months of administration clearly

increased the SVR rate in genotype 1 patients, compared with 6 months of administration. However, in genotype 2 patients, there was no significant difference between 6 and 12 months of administration. The standard dose of IFN used in Europe and the United States, based on early clinical studies, has been 3 MU three times a week, with the result that European and U.S. therapeutic results after 6 months of IFN monotherapy are generally lower than those in Japan.^{10,11} In Europe and the United States, the superiority of the 6-MU dose over a 3-MU dose has been shown by subsequent controlled studies, and many other clinical studies have shown the superiority of 12 months of therapy over 6 months.¹²⁻¹⁴ The SVR rate for genotype 1 patients with a high viral load improved with IFN therapy of extended duration, shown first for IFN monotherapy and later for the combination of IFN with ribavirin.¹⁵⁻¹⁷

Based on these findings, administration of IFN for 12 months was approved early in Europe and the United States. In Japan, the 6-month limit for IFN therapy was removed in 2002, and self-injection of IFN was approved in 2005. These measures make it easier for patients to undergo long-term treatment.

Development of IFN preparations: introduction of PEG-IFN

The type I IFNs include IFN α , IFN β , IFN ω , and IFN λ , all of which share cell-surface receptor and intracellular pathways of action. IFN agents are used in various preparations. In the United States, recombinant IFN α -2b and IFN α -2a were initially approved. In Japan, in addition to these two preparations, natural IFN α and IFN β can be used. These conventional preparations are considered to be of equal efficacy, although a few differences in the incidences of neutralizing antibodies and adverse effects have been noted.¹⁸ Subsequently, a special agent, consensus IFN, was developed and put into clinical use.¹⁹ It was designed by selecting the most frequently occurring amino acid at each site of the amino acid sequences of 13 known IFN α subtypes. Consensus IFN is considered to have a potent antiviral effect in genotype 1 patients with a high viral load, but it is still considered to be a conventional IFN agent.

Revolutionary progress in the development of IFN agents was recorded with the development of PEG-IFN and its introduction to clinical use. Pegylation is defined as modification of a drug by the addition of an artificial polymer, polyethylene glycol (PEG), for the purpose of delaying drug elimination, lowering its antigenicity, and modifying the drug's effect. Conventional IFN agents, with approximately 8-h elimination half-lives, require a dosing interval of 1 or 2 days to maintain an effective blood concentration.^{20,21} The most beneficial effect of PEG-IFN is that it delays drug elimination, making it

possible to maintain a stable blood concentration with once-weekly administration.²² Currently, two PEG-IFN preparations are available: recombinant IFN α -2a and IFN α -2b, which are covalently bound to 40-kDa PEG and 12-kDa PEG, respectively. Both are thought to have about equal efficacy, but they have not been compared in clinical trials.

European and U.S. controlled studies have shown that PEG-IFN agents are generally more effective, both in monotherapy²³⁻²⁵ and in combination with ribavirin, than conventional IFN agents.^{26,27} In Japan, clinical studies have shown that PEG-IFN agents are not inferior to conventional IFN agents. However, no study has shown PEG-IFN agents to be significantly superior with respect to SVR, partly, perhaps, because the usual dose of control IFN agents used in Europe and the United States is 3 MU, which is less than that used in Japan. In sum, PEG-IFN is at least equivalent to conventional IFN in effectiveness, and it appears to be highly tolerable because it can be administered just once a week.

The adverse effects of IFN are classified into two types: those that occur soon after the start of administration, and those that manifest during long-term administration.²⁸ The former type includes flu-like symptoms, such as a high fever, headache, and myalgia, and abnormal blood test results such as thrombocytopenia and leukopenia. Effects seen with long-term administration include a wide variety of symptoms, such as pruritus, alopecia, fundal hemorrhage, depression, thyroid dysfunction, diabetes mellitus, pulmonary fibrosis, and cardiac arrhythmia. Adverse effects of PEG-IFN are similar to those of conventional IFN and are characterized by mild influenza-like symptoms during the early stage of administration and comparatively severe cytopenia. The occurrence of acute thrombocytopenia in the late stage of administration of PEG-IFN α -2a has also been noted. More caution is needed with respect to the occurrence of adverse effects of PEG-IFN owing to its delayed clearance.

Combination therapy: introduction of ribavirin

Ribavirin, developed in 1972, is a synthetic nucleic acid analog with a purine skeleton. It has antiviral activity *in vitro* to a wide variety of RNA and DNA viruses, and it is orally administered. Ribavirin has not been approved in Japan as an antiviral agent for monotherapy, but it has been approved in Europe and the United States for various viral diseases, such as severe respiratory syncytial virus infection in children. Its antiviral effect against HCV has not been proved by studies on monotherapy for hepatitis C.²⁹ In 1998, however, the combination of ribavirin with IFN was reported to have achieved a significantly higher SVR rate compared with IFN

monotherapy.^{15,16,30,31} These reports were followed by large-scale clinical studies in Europe and United States^{26,27} showing that a combination of PEG-IFN and ribavirin produces better results than one of IFN and ribavirin. With both combinations, 48 weeks of administration to genotype 1 patients achieved a significantly higher SVR rate than 24 weeks of administration.^{15,16,32} For other patients, no significant difference was seen between groups receiving 24 or 48 weeks of therapy, and the 24-week administration period was reported to be sufficiently effective.

In Japan, a 48-week, multicenter, randomized, controlled study³³ was conducted on combinations of 6MU IFN α -2b with ribavirin and 1.5 μ g/kg PEG-IFN α -2b with ribavirin administered to genotype 1b patients with a high load of HCV-RNA, determined to be 100 KIU/ml or higher using Amplicor (by the original PCR method). Oral doses of ribavirin administered were 600 mg/day for patients weighing less than 60 kg, 800 mg/day for those weighing at least 60 kg but less than 80 kg, and 1000 mg/day for those weighing 80 kg or more. IFN α -2b was administered six times a week for the first 2 weeks and three times a week for the following 46 weeks, while PEG-IFN α -2b was administered once a week. The results for 506 patients indicated high rates of viral elimination by both therapies. The combination of PEG-IFN α -2b plus ribavirin and that of IFN α -2b and ribavirin achieved SVR in 121/254 patients (47.6%) and 113/252 patients (44.8%), respectively, a difference that was not significant. Based on this phase 3 study, 48 weeks of PEG-IFN α -2b and ribavirin combination therapy was approved for genotype 1 patients with a high viral load in Japan in 2004.

The adverse effects of ribavirin include hemolytic anemia and potential teratogenicity. Caution must be exercised with ribavirin administration when there is coexisting anemia or coronary heart disease. Contraception is also required during administration of ribavirin and up to 6 months after the end of its administration. Ribavirin is contraindicated for patients with renal failure, because it is excreted by the kidney and cannot be eliminated by dialysis.

Recent developments in PEG-IFN and ribavirin therapy

Coadministration of PEG-IFN and ribavirin has been established as the standard regimen of antiviral therapy for hepatitis C,³⁴ and the following questions next arise. How long should the dosing period be for this combination? How can its adverse effects be ameliorated and the treatment successfully completed? To what extent can this combination treatment be applied? Recent developments offer responses to these questions.

Exploring necessary and sufficient dosing periods: the impact of viral kinetics study

Usually the duration of coadministration of PEG-IFN and ribavirin is 48 weeks for difficult cases (e.g., genotype 1 patients with a high viral load) and 24 weeks for other cases, with expected SVR rates of approximately 50% and 80%, respectively.³² Some studies have suggested that higher doses of ribavirin based on body weight are more effective for genotype 1, while a lower dose (fixed dose at 800 mg/day) is sufficient for viral genotypes other than genotype 1. To date, a variety of factors, both viral and host, that correlate with a sustained response to the combination therapy have been noted (Fig. 2). In contrast to viral factors, however, most host factors do not have a strong impact on the various treatment regimens. Recently, the viral kinetics after the start of therapy has been noted to be a useful early indicator of viral elimination, which is usually determined 24 weeks after the end of therapy.²⁰ To find out whether SVR is related to the rate of inhibition of viral replication after the start of PEG-IFN plus ribavirin combination therapy, Davis et al.³⁵ carried out a retrospective analysis of a controlled clinical study conducted by Manns et al.²⁶ In the clinical study, PEG-IFN α -2b (1.5 μ g/kg per week) and ribavirin (800 mg/day) were coadministered to 511 patients with chronic hepatitis C for 48 weeks. If an early virologic response (EVR) is defined as a viral load decrease of 2 log or more or viral elimination after 12 weeks of treatment, then 71.8% of the patients who experienced EVR—74.4% of all patients—achieved SVR. Importantly, none of the patients who did not experience EVR achieved SVR. Similarly, with therapy with PEG-IFN α -2a (180 μ g/week) plus ribavirin (1000 or 1200 mg/day, depending on body weight) for 48 weeks ($n = 453$), only 2 of 63 patients who did not experience EVR achieved SVR.²⁷ These findings show that EVR has negative predictive value, and therefore, if viral elimination is the aim of the treatment and if adverse effects cannot be negligible, the treatment should be discontinued in patients not displaying EVR. This “12-week rule” applies only to patients with viral genotype 1.³⁶

The relationship between the time of becoming HCV-negative and SVR has also been examined in Japan in the above-mentioned clinical study³³ of PEG-IFN α -2b plus ribavirin. SVR rates for patients who became HCV-negative at 4, 12, or 24 weeks (23, 121, and 33 patients, respectively) were 100%, 71.1% and 36.4%, respectively. None of the 15 patients who experienced viral elimination after 24 weeks achieved SVR. Therefore, 24 weeks of additional administration to patients with no viral elimination within the initial 24 weeks produces no benefit.

Factors correlated with a successful response to combo therapy

Viral factors

- Non-1 genotypes
- Lower viral load

Host Factors

- Female sex (paradoxically male sex in most Japanese studies)
- Younger age
- Less fibrosis
- Non-African American race
- Absence of hepatic steatosis

Response and adherence to treatment

- Presence of a rapid initial first-phase decline followed by a more gradual second-phase decline in serum HCV RNA levels
- Maintenance of the initial prescribing dosing

Fig. 2. Factors correlated with a successful response to combination therapy with pegylated interferon and ribavirin in chronic hepatitis C. HCV, hepatitis C virus

Genotype 1 patients who do not experience EVR are very intractable, as shown above. In other words, 48 weeks of therapy with PEG-IFN and ribavirin may be too short to maximize SVR in genotype 1 patients.³⁷ The usefulness of long-term administration for 48 weeks or longer is being investigated to improve the rate of achievement of SVR in such patients. Buti et al.³⁸ published a promising report on extending therapy with PEG-IFN plus ribavirin to 72 weeks for late virologic responders. They selected nine genotype 1 patients being treated with PEG-IFN α -2b (1.0 μ g/kg) plus ribavirin (800 mg/day) who cleared HCV RNA between weeks 12 and 24 for therapy prolonged to 72 weeks. Eight patients completed therapy, and at week 24 of follow-up, seven maintained SVR and one had relapsed. A Spanish multicenter, randomized controlled study, in which patients with chronic hepatitis C who did not become HCV negative by 4 weeks of coadministration of PEG-IFN α -2a (180 μ g/week) and ribavirin (800 mg/day) (about two-thirds of all patients) were randomized to groups receiving 48 weeks or 72 weeks of therapy, found that the group receiving 72 weeks of therapy achieved a significantly higher rate of SVR than the group receiving 48 weeks of therapy. On the other hand, a recent clinical trial showed that genotype 1 patients who were HCV RNA-negative after 4 weeks of coadministration of PEG-IFN α -2a (180 μ g/week) and ribavirin (1000 or 1200 mg/day) achieved an SVR rate of 66% with a further 20 weeks of therapy.³⁹ Unfortunately, this study did not randomize the patients to compare 24 weeks of therapy with a 48-week therapy period. The study, however, does show that 24 weeks of

therapy can achieve relatively high rates of viral elimination for these genotype 1 “super-responders.”

For other, non-1 viral genotypes, studies are being done to identify a dosing period shorter than 24 weeks that can be used to achieve sufficient SVR. In one study, genotype 2 and 3 patients were given PEG-IFN α -2b (1.0 μ g/kg each week) and ribavirin (1000 or 1200 mg/day, based on body weight), and those who experienced viral elimination after 4 weeks of therapy were assigned to 24-week or 12-week therapy groups. The results showed that the SVR rate for the 12-week group was the same as that for the 24-week group, indicating that 12 weeks of combination therapy is sufficient for these patients.⁴⁰ Similar data have also been reported for PEG-IFN α -2a (180 μ g/week) plus ribavirin (800 to 1200 mg/day) therapy.⁴¹

As mentioned above, for treatment of non-1 viral genotypes and some genotype 1 patients, sufficient SVR rates can be achieved and unnecessary treatment avoided by adopting the dosing period by using the early viral inhibition effect as an indicator. The early viral kinetics can be also applied to identify more difficult to treat patients with viral genotype 1, who can then be given longer treatment to improve SVR rates (Fig. 3).

Reducing cytopenic effects and improving compliance: the use of hematopoietic growth factors

Patient compliance has been noted by many clinical studies to be the largest factor contributing to the therapeutic effect of PEG-IFN plus ribavirin combination

therapy (Fig. 2). Compliance can be divided into those factors related to patient adherence to the regimen and dose interruptions or modifications mandated by the physician in response to cytopenia, rash, gastrointestinal symptoms, or depression. McHutchison et al.⁴² outlined an "80:80:80 rule" in genotype 1 patients; that is, the doses of PEG-IFN and ribavirin and the dosing period should exceed 80% of the initial plan to achieve a sufficient SVR rate. Early dose reduction within 12 weeks is more harmful than later dose reduction. To maximize viral clearance of the PEG-IFN and ribavirin combination therapy, countermeasures are needed against adverse effects to improve patient compliance.

Compared with IFN monotherapy, combination therapy is characterized by additional adverse effects represented by hemolytic anemia. If anemia occurs, the dose of ribavirin must be reduced or the administration of ribavirin must be discontinued. To help avoid this adverse effect, attention is being drawn to drug intervention with erythropoietin. An 8-week, double-blind study was conducted in which epoetin alpha 4000 U/week or a placebo was given to patients who experienced a decrease in hemoglobin (Hb) levels to 12 g/dl or less during coadministration of PEG-IFN and ribavirin in the United States, and the dose of ribavirin, Hb levels, and quality of life (QOL) were compared at the end of the study.⁴³ Compared with the placebo group, the reduction in Hb levels was significantly inhibited in the epoetin alpha group; thus, reduction of the ribavirin dose could be avoided. Inhibition of the reduction in Hb levels also improved QOL.⁴⁴ Similarly, granulocyte-colony stimulating factor (G-CSF) is expected to be useful for avoiding leukocytopenia induced by PEG-IFN and ribavirin combination therapy. Prevention of adverse effects with hematopoietic growth factors may be a promising measure to allow the maintenance of the therapy protocol and to improve therapeutic outcomes.

Challenging special patient groups: chronic hepatitis C with persistently normal ALT levels

Persistently normal ALT levels are observed in 20%–30% of chronic HCV-infected patients among the general public. Such patients are sometimes called asymptomatic HCV carriers. Most of them present a picture of histologically minimal or mild chronic hepatitis; it is rare for the liver to be normal. Progression of fibrosis is noted in fewer than 10% of the patients. For this reason, the expression "chronic hepatitis C patients with persistently normal ALT levels" is often preferred to "asymptomatic HCV carriers." There was strong resistance against using IFN therapy for such patients in the 1990s^{45,46} for both active and passive reasons. The former included a lower viral elimination effect, or SVR, compared with general hepatitis C patients, and

the report of abnormal ALT levels in a high percentage of patients due to IFN therapy in early studies of asymptomatic HCV carriers.^{47,48} Recent studies have shown that IFN monotherapy⁴⁹ and IFN plus ribavirin combination therapy^{50,51} can help patients with persistently normal ALT levels achieve the same level of SVR as patients with abnormal ALT levels. The percentage of patients who display an increase in the ALT level in response to IFN therapy is also lower than that in the early studies.⁵¹ Therefore, the active reasons against using IFN therapy for patients with persistently normal ALT levels can no longer be supported. The passive reason, that there is no evidence of improved long-term prognosis in this patient group by IFN therapy, still remains.

HCV patients with normal ALT levels have been not eligible for large-scale clinical studies, causing there to be a deceptively low level of evidence regarding the efficacy of antiviral therapy in such patients. However, the potential importance of antiviral therapy for such patients has been gaining attention in recent years, and an international, multicenter, randomized, controlled study of PEF-IFN α -2a plus ribavirin combination therapy has been conducted.⁵² Eligible participants were 491 HCV RNA-positive patients whose ALT levels measured three times or more at intervals of at least 4 weeks did not exceed the upper limit of the normal ALT range. The patients were randomized at the proportion of 3:3:1 into three groups: patients receiving 24 weeks of therapy with PEF-IFN α -2a (180 μ g/week) and ribavirin (800 mg/day), those receiving 48 weeks of PEF-IFN α -2a (180 μ g/week) and ribavirin (800 mg/day), and a control group that did not receive any treatment. Acute exacerbation of ALT levels that exceeded ten times the upper limit was observed in two patients (one in the 24-week therapy group and one in the control group). The results regarding treatment effectiveness were identical to those for chronic hepatitis C patients with high ALT levels previously published by Hadziyannis et al.³² Thus, a dosing period based on the algorithm established for chronic hepatitis C patients with abnormal ALT levels can be recommended for PEG-IFN plus ribavirin combination therapy for HCV-infected patients with persistently normal ALT levels.

Such findings strongly suggest that HCV-infected persons with persistently normal ALT levels should be considered eligible for IFN therapy. The 2004 American Association for the Study of Liver Diseases (AASLD) best-practice guideline³⁶ recommended as follows: "Regardless of serum aminotransferase levels, the decision to initiate therapy with interferon and ribavirin should be individualized based on the severity of liver diseases by liver biopsy, the potential serious side effects, the likelihood of response, and the presence of comorbid

conditions." What is crucial is not the ALT level but whether to treat the patient if his/her liver disease is not severe.

Future antiviral therapy for hepatitis C

IFN plus ribavirin combination therapy brought about substantial improvement in comparison with the IFN therapy introduced in the 1990s. This combination may lead to high viral elimination primarily because it decreases the incidence of relapse in patients who have become HCV-negative during the therapy. According to an analysis of patient characteristics by the aforementioned Japanese clinical study³³ of PEG-IFN α -2b plus ribavirin combination therapy for genotype 1b patients with high viral load, SVR rates in treatment-naïve patients, relapsers, and nonresponders were 43.1% (59/137 patients) 62.6% (57/91 patients), and 19.2 (5/26 patients), respectively. The fact that relapsers achieved higher SVR rates than treatment-naïve patients suggests that PEG-IFN plus ribavirin combination therapy maximizes the therapeutic effect of IFN and encourages complete viral elimination in IFN-responding patients. On the other hand, the low SVR rate in nonresponders indicates that PEG-IFN plus ribavirin combination therapy is not always useful in patients who do not respond to IFN. To improve SVR rates in such patients, more-effective antiviral agents other than IFN must be developed. Furthermore, as described earlier, PEG-IFN plus ribavirin combination therapy induces a variety of adverse effects. Clearly, safer and better tolerated therapies are needed.

Promising agents for future anti-HCV therapies are classified as HCV-specific inhibitors targeting its protease and polymerase activities, IFN inducers, or less-toxic ribavirin-like agents. A number of drugs are in preclinical or clinical trials.

HCV protease inhibitors

HCV encodes at least four enzymes required for virus replication. They include NS2/3 autoprotease, NS3 helicase, NS3/4A serine protease, and NS5B RNA-dependent RNA polymerase. Intensive work on developing specific inhibitors has focused on the last two.

SCH 503034 is a novel, orally active HCV protease inhibitor that exhibits potent and specific antiviral activity in HCV replicon assays. Recently, a phase 1b clinical trial was conducted for both monotherapy⁵³ and combination therapy with PEG-IFN α -2b.⁵⁴ SCH 503034 exhibited dose-dependent HCV antiviral activity in genotype 1 patients in whom PEG-IFN therapy had previously been unsuccessful. In combination with PEG-IFN α -2b, SCH 503034 had at least an additive

effect on HCV suppression. VX-950 is an orally administered highly selective peptidomimetic inhibitor of HCV NS3/4A protease. In a phase 1b clinical trial, VX-950 was well tolerated for 5 to 14 days in both healthy subjects and patients with viral genotype 1, with no serious adverse effects. VX-950 showed a 4.4-log reduction in median HCV RNA at the end of 14 days of therapy.⁵⁵

In addition of its critical role in virus replication, the NS3/4A protease also plays a role in suppressing the cellular antiviral response. Active NS3/4A prevents the phosphorylation and activation of interferon regulatory factor (IRF)-3 and the triggering of downstream IFN-induced antiviral effector genes.^{56,57} IRF-3 activity has been shown to be restored by a HCV protease inhibitor. Thus, an effective protease inhibitor may block not only RNA replication but also the ability of HCV to evade innate antiviral responses.

HCV polymerase inhibitors

Valopicitabine (NM283) is a 3'-valyl prodrug of a nucleoside analog that exhibits anti-HCV activity via inhibition of viral RNA polymerase. Valopicitabine is currently in phase 2 clinical development for the treatment of chronic hepatitis C. In a phase 2a trial, valopicitabine demonstrated potent anti-HCV activity when administered in combination with PEG-IFN α -2b, with 4.5-log serum HCV RNA reduction at 6 months and no obvious viral breakthroughs. In a phase 2b clinical trial, the combination therapy was also effective for patients previously unresponsive to PEG-IFN and ribavirin combination therapy.⁵⁸

Since HCV has a higher intrinsic mutation rate than HIV, resistance is expected to be a problem with the use of any type of HCV-specific inhibitor targeting NS3/4A or NS5B proteins. To suppress the risk of a possible escape mutant, combination therapy with PEG-IFN may be better than monotherapy because the former can more efficiently suppress the levels of HCV replication. In the future, a combination of two or three different types of HCV inhibitors may offer a promising approach, similar to HIV cocktail therapy.

Immune modulators

Successful spontaneous clearance of HCV infection is thought to require both innate (e.g., direct antiviral activities by cytokines and natural killer cells) and adaptive (T cell-mediated) immune responses. Chronic HCV infection is characterized by an inadequate immune response that fails to clear the virus.⁵⁹ Immune modulators, alone or in combination with direct antiviral agents such as IFN and HCV inhibitors, represent a possible opportunity to improve HCV clearance.




Fig. 3. Various treatment regimens of pegylated IFN and ribavirin combination therapy. *RVR*, rapid virologic response; *EVR*, early virologic response

CPG 10101 is a synthetic agonist of toll-like receptor (TLR) 9. HCV-infected patients receiving CPG 10101 subcutaneously had a more than 1-log reduction in HCV viral load while on therapy.⁶⁰ Further development of this agent will continue in conjunction with PEG-IFN and ribavirin.

Isatorbine is a TLR7 agonist. In a proof-of-concept clinical study, intravenous injection of isatorbine once daily for 7 days to patients chronically infected with HCV yielded a significant reduction of serum HCV RNA that correlated with induction of 2',5'-oligoadenylate synthetase. Recently, the orally available prodrug of isatorbine, ANA975, was developed and studied in healthy phase 1 volunteers and showed promising pharmacokinetics and tolerability.⁶¹

Ribavirin-like agents

The addition of ribavirin to IFN therapy more than doubled the SVR rate, although its mechanism of action is unknown.⁶² Furthermore, higher doses of ribavirin clearly improved response rates in genotype 1 patients.^{32,63} However, ribavirin-induced hemolytic anemia is a major obstacle to implementation of a higher dosage regimen and limits its use in patients with comorbidities. To develop a better tolerated combination therapy, ribavirin-like agents lacking a hemolytic effect are needed. Viramidine is a ribavirin prodrug that is metabolized primarily in the liver. In a phase 2 study,

fewer patients receiving viramidine developed anemia compared with those given ribavirin, but they also showed lower SVR rates.⁶⁴ Phase 3 trials have been undertaken of both PEG-IFN α -2a and PEG-IFN α -2b combined with viramidine in comparison with the combination with ribavirin.

Conclusion: viewpoints other than SVR

IFN treatment of patients with chronic hepatitis C were initially based on observations of its biochemical effects, before the discovery of HCV. Subsequently, evaluation of SVR at 6 months after stopping therapy as a clear end point made it possible to assess therapeutic results in a scientific manner. IFN therapy has been developing over the past decade, with the aim of improving the SVR rate, and higher rates are expected to be achieved with new, more specific antiviral agents.

The question arises as to what the ultimate purpose of hepatitis C treatment is. The answer is that it is the prevention of liver-related death of HCV-infected patients by suppressing progression to decompensated liver disease and liver carcinogenesis (Fig. 4), meaning that hepatitis C is not just an infectious disease, but a potentially serious liver disease. From this point of view, SVR is no more than a surrogate marker—albeit a very strong one—to improve the prognosis of HCV-infected patients. Hepatocellular cancer occurs even in patients




Fig. 4. Effects of IFN-based therapy in relation to the purpose of treatment for chronic hepatitis C. Retrospective analysis of rates of hepatocellular carcinoma and liver-related death after IFN monotherapy have shown a reduction in risk, especially in patients with moderate liver fibrosis⁶⁵⁻⁶⁹

who have experienced SVR, although its incidence is substantially lower in those patients than that in untreated patients or nonresponders. Thus, routine hepatocellular cancer screening is essential even after patients have experienced SVR, and early treatment is indispensable if it occurs. On the other hand, the cumulative incidence of hepatocellular carcinoma is clearly suppressed around half in even relapsers at least for 5 years after the termination of therapy compared with that in untreated patients.⁶⁵ Therefore, the therapeutic effect of IFN therapy should be evaluated not only on the basis of the SVR rate but also from the more important viewpoint of inhibition of hepatocellular cancer. In this context, repeated IFN therapy, for example every 5 years, for relapsers, and long-term, low-dose IFN therapy for nonresponders should also be considered until a new era dawns of treating hepatitis C with novel anti-HCV agents.

References

1. Choo QL, Kuo G, Weiner AJ, Overby LR, Bradley DW, Houghton M. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. *Science* 1989;244:359-62.
2. Anonymous. Global surveillance and control of hepatitis C. Report of a WHO consultation organized in collaboration with the Viral Hepatitis Prevention Board, Antwerp, Belgium. *J Viral Hepat* 1999;6:35-47.
3. Hoofnagle JH, Mullen KD, Jones DB, Rustgi V, Di Bisceglie A, Peters M, et al. Treatment of chronic non-A, non-B hepatitis with recombinant human alpha interferon. A preliminary report. *N Engl J Med* 1986;315:1575-8.
4. Davis GL, Balart LA, Schiff ER, Lindsay K, Bodenheimer HC Jr, Perrillo RP, et al. Treatment of chronic hepatitis C with recombinant interferon alpha. A multicenter randomized, controlled trial. *N Engl J Med* 1989;321:1501-6.
5. Di Bisceglie AM, Martin P, Kassianides C, Lisker-Melman M, Murray L, Waggoner J, et al. Recombinant interferon alpha therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial. *N Engl J Med* 1989;321:1506-10.
6. Hagiwara H, Hayashi N, Mita E, Ueda K, Takehara T, Kasahara A, et al. Detection of hepatitis C virus RNA in serum of patients with chronic hepatitis C treated with interferon- α . *Hepatology* 1992;15:37-41.
7. Hagiwara H, Hayashi N, Mita E, Takehara T, Kasahara A, Fusamoto H, et al. Quantitative analysis of hepatitis C virus RNA in serum during interferon alpha therapy. *Gastroenterology* 1993;104:877-883.
8. Mita E, Hayashi N, Hagiwara H, Ueda K, Kanazawa Y, Kasahara A, et al. Predicting interferon therapy efficacy from hepatitis C virus genotype and RNA titer. *Dig Dis Sci* 1994;39:977-982.
9. Kasahara A, Hayashi N, Hiramatsu N, Oshita M, Hagiwara H, Katayama K, et al. Ability of prolonged interferon treatment to suppress relapse after cessation of therapy in patients with chronic hepatitis C: a multicenter randomized controlled trial. *Hepatology* 1995;21:291-7.
10. Marcellin P, Boyer N, Giostra E, Degott C, Courouce AM, Degos F, et al. Recombinant human alpha-interferon in patients with chronic non-A, non-B hepatitis: a multicenter randomized controlled trial from France. *Hepatology* 1991;13:393-7.
11. Causse X, Godinot H, Chevallier M, Chossegros P, Zoulim F, Ouzan D, et al. Comparison of 1 or 3 MU of interferon alpha-2b and placebo in patients with chronic non-A, non-B hepatitis. *Gastroenterology* 1991;101:497-502.
12. Lindsay KL, Davis GL, Schiff ER, Bodenheimer HC, Balart LA, Dienstag JL, et al. Response to higher dose of interferon alpha-2b in patients with chronic hepatitis C: a randomized multicenter trial. Hepatitis Interventional Therapy Group. *Hepatology* 1996;24:1034-40.
13. Poynard T, Leroy V, Cohard M, Thevenot T, Mathurin P, Polon P, et al. Meta-analysis of interferon randomized trials in the treatment of viral hepatitis: effect of dose and duration. *Hepatology* 1996;24:778-89.
14. Tassopoulos NC, Karvountzis G, Touloumi G, Delladetsima JK, Papatheodoridis GV, Katsoulidou A, et al. Comparative efficacy of a high or low dose of interferon alpha 2b in chronic hepatitis C: a randomized controlled trial. *Am J Gastroenterol* 1996;91:1734-8.
15. Poynard T, Marcellin P, Lee SS, Niederau C, Minuk GS, Ideo G, et al. Randomized trial of interferon alpha-2b and ribavirin for 48 weeks or for 24 weeks versus interferon alpha-2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. *Lancet* 1998;352:1426-32.
16. McHutchison JG, Gordon SC, Schiff ER, Shiffman ML, Lee WM, Rustgi VK, et al. Interferon alpha-2b and ribavirin as initial treatment of relapse of chronic hepatitis C. *N Engl J Med* 1998;339:1485-92.

17. Hiramatsu N, Kasahara A, Nakanishi F, Toyama T, Tsujii M, Tsuji S, et al. The significance of interferon and ribavirin combination therapy followed by interferon monotherapy for patients with chronic hepatitis C in Japan. *Hepatol Res* 2004;29:142-7.
18. Rumi M, Del Ninno E, Parravicini ML, Romeo R, Soffredini R, Donato MF, et al. A prospective randomized trial comparing lymphoblastoid to recombinant interferon alpha 2a as therapy for chronic hepatitis C. *Hepatology* 1996;24:1366-70.
19. Tong MJ, Reddy KR, Lee WM, Pockros PJ, Hoefs JC, Keeffe EB, et al. Treatment of chronic hepatitis C with consensus interferon: a multicenter, randomized, controlled trial. Consensus Interferon Group. *Hepatology* 1997;26:747-54.
20. Neumann AU, Lam NP, Dahari H, Gretch DR, Wiley TE, Layden TJ, et al. Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon- α therapy. *Science* 1998;282:103-7.
21. Zeuzem S, Schmidt JM, Lee JH, Ruster B, Roth WK. Effect of interferon alpha on the dynamics of hepatitis C virus turnover in vivo. *Hepatology* 1996;23:366-71.
22. Nieforth KA, Nadeau R, Patel IH, Mould D. Use of an indirect pharmacodynamic stimulation model of MX protein induction to compare in vivo activity of interferon alpha-2a and a polyethylene glycol-modified derivative in healthy subjects. *Clin Pharmacol Ther* 1996;59:636-46.
23. Zeuzem S, Feinman SV, Rasenack J, Heathcote EJ, Lai MY, Gane E, et al. Peginterferon alpha-2a in patients with chronic hepatitis C. *N Engl J Med* 2000;343:1666-72.
24. Heathcote EJ, Shiffman ML, Cooksley WG, Dusheiko GM, Lee SS, Balart L, et al. Peginterferon alpha-2a in patients with chronic hepatitis C and cirrhosis. *N Engl J Med* 2000;343:1673-80.
25. Lindsay KL, Trepo C, Heintges T, Shiffman ML, Gordon SC, Hoefs JC, et al. Hepatitis Interventional Therapy Group. Lindsay K, et al. A randomized, double-blind trial comparing PEGylated interferon alpha-2b to interferon alpha-2b as initial treatment for chronic hepatitis C. *Hepatology* 2001;34:395-403.
26. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindoller R, et al. Peginterferon alpha-2b plus ribavirin compared with interferon alpha-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomized trial. *Lancet* 2001;358:958-65.
27. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Goncalves FL Jr, et al. Peginterferon alpha-2a plus ribavirin for chronic hepatitis C virus infection. *N Engl J Med* 2002;347:975-82.
28. Dusheiko G. Side effects of alpha interferon in chronic hepatitis C. *Hepatology* 1997;26:112S-21S.
29. Bodenheimer HC Jr, Lindsay KL, Davis GL, Lewis JH, Thung SN, Seeff LB. Tolerance and efficacy of oral ribavirin treatment of chronic hepatitis C: a multicenter trial. *Hepatology* 1997;26:473-7.
30. Davis GL, Esteban-Mur R, Rustgi V, Hoefs J, Gordon SC, Trepo C, et al. Interferon alpha-2b alone or in combination with ribavirin for the treatment or relapse of chronic hepatitis C. *N Engl J Med* 1998;339:1493-9.
31. Reichard O, Norkrans G, Fryden A, Braconier JH, Sonnerborg A, Weiland O. Randomized double-blind, placebo-controlled trial of interferon alpha-2b with and without ribavirin for chronic hepatitis C. *Lancet* 1998;351:83-6.
32. Hadziyannis SJ, Sette Jr. H, Morgan TR, Balan V, Diago M, Marcellin P, et al. Peginterferon- α 2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. *Ann Intern Med* 2004;140:346-55.
33. Iino S, Okita K, Omata M, Kumada H, Hayashi N, Tanikawa K. Clinical efficacy of PEG-Interferon α -2b and ribavirin combination therapy for 48 weeks in chronic hepatitis C patients with genotype 1 and high viral load—retrospective comparison with Interferon α -2b and ribavirin combination therapy for 24 weeks. *KanTanSui* 2004;49:1099-121.
34. Di Bisceglie AM, Hoofnagle JH. Optimal therapy of hepatitis C. *Hepatology* 2002;36:S121-7.
35. Davis GL, Wong JB, McHutchison JG, Manns MP, Harvey J, Albrecht J. Early virologic response to treatment with peginterferon alpha-2b plus ribavirin in patients with chronic hepatitis C. *Hepatology* 2003;38:645-52.
36. Strader DB, Wright T, Thomas DL, Seeff LB, American Association for the Study of Liver Diseases. Diagnosis, management, and treatment of hepatitis C. *Hepatology* 2004;39:1147-71.
37. Drusano GL, Preston SL. A 48-week duration of therapy with pegylated interferon α 2b plus ribavirin may be too short to maximize long-term response among patients infected with genotype-1 hepatitis C virus. *J Infect Dis* 2004;189:964-70.
38. Buti M, Valdes A, Sanchez-Avila F, Esteban R. Extending combination therapy with peginterferon alpha-2a plus ribavirin for genotype 1 chronic hepatitis C late responders: a report of 9 cases. *Hepatology* 2003;37:1226-7.
39. Ferenci P, Bergholz U, Laferl H, Gurguta C, Maieron A, Gschwantler M, et al. Is shorter treatment with peginterferon alpha-2a (40KD) plus ribavirin possible in HCV genotype 1 "super-responder"? preliminary results of a prospective randomized clinical trial. *Hepatology* 2005;42:218A.
40. Mangia A, Santoro R, Minerva N, Ricci GL, Carretta V, Persico M, et al. Peginterferon alpha-2b and ribavirin for 12 vs. 24 weeks in HCV genotype 2 or 3. *N Engl J Med* 2005;352:2609-17.
41. Wagner M, Huber M, Berg T, Hinrichsen H, Rasenack J, Heintges T, et al. Peginterferon- α -2a (40KD) and ribavirin for 16 or 24 weeks in patients with genotype 2 or 3 chronic hepatitis C. *Gastroenterology* 2005;129:522-7.
42. McHutchison JG, Manns M, Patel K, Poynard T, Lindsay KL, Trepo C, et al. Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C. *Gastroenterology* 2002;123:1061-9.
43. Afdhal NH, Dieterich DT, Pockros PJ, Schiff ER, Shiffman ML, Sulkowski MS, et al. Epoetin alpha maintains ribavirin dose in HCV-infected patients: a prospective, double-blind, randomized controlled study. *Gastroenterology* 2004;126:1302-11.
44. Pockros PJ, Shiffman ML, Schiff ER, Sulkowski MS, Younossi Z, Dieterich DT, et al. Epoetin alpha improves quality of life in anemic HCV-infected patients receiving combination therapy. *Hepatology* 2004;40:1450-8.
45. Marcellin P, Levy S, Erlinger S. Therapy of hepatitis C: patients with normal aminotransferase levels. *Hepatology* 1997;26:133S-6S.
46. Anonymous. EASL international consensus conference on hepatitis C. Consensus statement. *J Hepatol* 1999;30:956-62.
47. Serfaty L, Chazouilleres O, Pawlotsky JM, Andreani T, Pellet C, Poupon R. Interferon alpha therapy in patients with chronic hepatitis C and persistently normal aminotransferase activity. *Gastroenterology* 1996;110:291-5.
48. Sangiovanni A, Morales R, Spinzi G, Rumi M, Casiraghi A, Ceriani R, et al. Interferon alpha treatment of HCV RNA carriers with persistently normal transaminase levels: a pilot randomized controlled study. *Hepatology* 1998;27:853-6.
49. Rossini A, Ravaggi A, Biasi L, Agostinelli E, Bercich L, Gazzola GB, et al. Virological response to interferon treatment in hepatitis C virus carriers with normal aminotransferase levels and chronic hepatitis. *Hepatology* 1997;26:1012-7.
50. Di Bisceglie AM, Thompson J, Smith-Wilkaitis N, Brunt EM, Bacon BR. Combination of interferon and ribavirin in chronic hepatitis C: re-treatment of non-responders to interferon. *Hepatology* 2001;33:704-7.
51. Hui CK, Monto A, Belaye T, Lau E, Wright TL. Outcomes of interferon α and ribavirin treatment for chronic hepatitis C in patients with normal serum aminotransferases. *Gut* 2003;52:1644-8.
52. Zeuzem S, Diago M, Gane E, Reddy KR, Pockros P, Prati D, et al. Peginterferon alpha-2a (40 kilodaltons) and ribavirin in patients with chronic hepatitis C and normal aminotransferase levels. *Gastroenterology* 2004;127:1724-32.
53. Zeuzem S, Sarrazin C, Rouzier R, Tarral A, Brion N, Forestier N, et al. Anti-viral activity of SCH 503034, a HCV protease inhibitor, administered as monotherapy in hepatitis C genotype-1 patients

- refractory to pegylated interferon (PEG-IFN- α). *Hepatology* 2005;42 (Suppl. 1):233A.
54. Zeuzem S, Sarrazin C, Wagner F, Rouzier R, Forester N, Gupta S, et al. Combination therapy with the HCV protease inhibitor, SCH 503034, plus Peg-Intron in hepatitis C genotype-1 Peg-Intron non-responder. *Hepatology* 2005;42 (Suppl. 1):276A.
 55. Reesink HW, Zeuzem S, Weegink CJ, Forester N, van Vliet A, McNair LA, et al. Final results of a phase 1b, multiple-dose study of VX-950, a hepatitis C virus protease inhibitor. *Hepatology* 2005;42 (Suppl. 1):234A.
 56. Foy E, Li K, Wang C, Sumpter R Jr, Ikeda M, Lemon SM, et al. Regulation of interferon regulatory factor-3 by the hepatitis C virus serine protease. *Science* 2003;300:1145–8.
 57. Foy E, Li K, Sumpter R Jr, Loo YM, Johnson CL, Wang C, et al. Control of antiviral defenses through hepatitis C virus disruption of retinoic acid-inducible gene-1 signaling. *Proc Natl Acad Sci U S A* 2005;102:2986–91.
 58. O'Brien C, Godofsky E, Rodriguez-Torres M, Afdhal N, Pappas SC, Pockros P, et al. Randomized trial of valopicitabine (NM283), alone or with peginterferon, vs. retreatment with peginterferon plus ribavirin (PEGIFN/RBV) in hepatitis C patients with previous non-response to PEGIFN/RBV: first interim results. *Hepatology* 2005;42 (Suppl. 1):234A.
 59. Takehara T, Hayashi N. Natural killer cells in hepatitis C virus infection: from innate immunity to adaptive immunity. *Clin Gastroenterol Hepatol* 2005;3:S78–81.
 60. Bacon BR, McHutchison JG, Gordon SC, Afdhal NH, Jacobson IM, Shiffman M, et al. Safety, pharmacodynamic (PD) and pharmacokinetic (PK) profiles of CPG 10101 (Actilon), a novel TLR9 agonist: comparison of normal volunteers and HCV infected individuals. *Gastroenterology* 2005;128 (Suppl 2):P-91.
 61. Kerr B, Bauman L, Webber S, Xiang A, Ng J, Kirkovsky L, et al. Pharmacokinetics, safety, and tolerability of the isatorbine oral prodrug ANA975 in a phase 1 healthy volunteer study. *Hepatology* 2005;42 (Suppl. 1):533A.
 62. Feld JJ, Hoofnagle JH. Mechanisms of action of interferon and ribavirin in treatment of hepatitis C. *Nature* 2005;436:967–72.
 63. Lindahl K, Stahle L, Bruchfeld A, Schvartz R. High-dose ribavirin in combination with standard dose PEGinterferon for treatment of patients with chronic hepatitis C. *Hepatology* 2005; 41:275–9.
 64. Gish RG, Nelson D, Arora S, Fried MW, Reddy KR, Xu Y, et al. Virologic response and safety outcomes in therapy-naïve patients treated for chronic hepatitis C with viremide in combination with pegylated interferon alpha-2a. *Gastroenterology* 2005;128 (Suppl 2):P-11.
 65. Kasahara A, Hayashi N, Mochizuki K, Takayanagi M, Yoshioka K, Kakumu S, et al. Risk factors for hepatocellular carcinoma and its incidence after interferon treatment in patients with chronic hepatitis C. Osaka Liver Disease Study Group. *Hepatology* 1998;27:1394–402.
 66. Kasahara A, Tanaka H, Okanoue T, Imai Y, Tsubouchi H, Yoshioka K, et al. Interferon treatment improves survival in chronic hepatitis C patients showing biochemical as well as virological responses by preventing liver-related death. *J Viral Hepat* 2004;11:148–56.
 67. Yoshida H, Shiratori Y, Moriyama M, Arakawa Y, Ide T, Sata M, et al. Interferon therapy reduces the risk for hepatocellular carcinoma: national surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. IIIT Study Group. Inhibition of Hepatocarcinogenesis by Interferon Therapy. *Ann Intern Med* 1999;131:174–81.
 68. Okanoue T, Itoh Y, Minami M, Sakamoto S, Yasui K, Sakamoto M, et al. Interferon therapy lowers the rate of progression to hepatocellular carcinoma in chronic hepatitis C but not significantly in an advanced stage: a retrospective study in 1148 patients. *Viral Hepatitis Therapy Study Group. J Hepatol* 1999; 30:653–9.
 69. Imai Y, Kawata S, Tamura S, Yabuuchi I, Noda S, Inada M, et al. Relation of interferon therapy and hepatocellular carcinoma in patients with chronic hepatitis C. Osaka Hepatocellular Carcinoma Prevention Study Group. *Ann Intern Med* 1998;129: 94–9.

Genotypes of hepatitis B virus (HBV) and those clinical characteristics in HBV carrier residents in Iwate, Japan: Results from health-screening program

Yukiho KASAI¹⁾, Kazuyuki SUZUKI¹⁾, Koichi ABE¹⁾, Tomiko KOYAMA²⁾ and Hiroaki OKAMOTO³⁾

¹⁾ Department of Medicine I, School of Medicine, Iwate Medical University, Morioka, Japan

²⁾ Health Science Association, Iwate, Japan

³⁾ Division of Virology, Department of Infection and Immunity, Jichi Medical School, Tochigi, Japan

岩手県におけるB型肝炎ウイルス (HBV) キャリア住民のHBV遺伝子型とその臨床的特徴

葛西幸穂¹⁾, 鈴木一幸¹⁾, 阿部弘一¹⁾, 小山富子²⁾, 岡本宏明³⁾

¹⁾ 岩手医科大学医学部, 内科学第1講座

²⁾ 岩手県予防医学協会

³⁾ 自治医科大学感染免疫学講座ウイルス部門

(Received on March 2, 2005 & Accepted on March 10, 2005)

Abstract

Recent studies indicate that genotypes of hepatitis B virus (HBV) are closely associated with pathogenesis and clinical outcome in HBV related liver diseases. However, the prevalence of these HBV genotypes and clinical features in HBV carriers remain unclear. From 1977 to 2004, a health-screening program in Iwate Prefecture identified 6,711 HBV carriers. A sample of 661 cases (male, 343; female, 318) was extracted using a stratified random sampling method. In addition, further 30 HBV carriers complicated with HCC during long-term follow-up were identified from the registration system for cancer patients of Iwate Prefecture, and they were enrolled in the study. HBV genotypes were determined using an enzyme linked immunosorbent assay kit. Distribution of HBV genotypes showed 19 (2.9%) with genotype A, 297

(44.9%) with genotype B, and 345 (52.2%) with genotype C. In 30 cases with HCC, genotype B and genotype C were 30% and 70%, respectively. HBV genotypes are closely associated with age, positive rate of HB e antigen (HBeAg), and fluctuation of serum alanine aminotransferase (ALT) levels during a follow-up. Cases that developed HCC with genotype B were found to be significantly older compared to genotype C. In conclusion, the prevalence of genotypes B and C were equal in HBV carriers residing in Iwate Prefecture. Differences between HBV genotypes, in particular genotypes B and C, were closely associated with positive rate of HBeAg, fluctuating serum ALT levels, and clinical outcomes of these carriers.

Key words : health-screening, HBV carrier residents, HBV genotype, HB e antigen, hepatocellular carcinoma

I. Introduction

In Asian and African countries, Hepatitis B virus (HBV) infection is still a major cause of

acute hepatitis (AH) and various forms of chronic infection, including asymptomatic HBV carrier state, chronic hepatitis (CH),

liver cirrhosis (LC), and hepatocellular carcinoma (HCC), because infection occurs predominantly through perinatal transmission to babies from carrier mothers who are positive for hepatitis B e antigen (HBeAg) in serum or through horizontal spread during infancy. Eight genotypes of HBV from A to H are currently recognized^{1, 2)} and have distinct geographical distributions³⁻⁷⁾. In general, while genotypes B and C frequently occur in Asia⁴⁻⁶⁾, genotypes A and D are common in Western countries⁷⁾. In Japanese patients with chronic HBV infection, the geographic distribution of genotypes B and C also differs among regions of Japan⁶⁾. In particular, genotype B is relatively frequent in the Tohoku region (the northern part of mainland Japan), which includes Iwate Prefecture, compared to other regions except the Okinawa region. Many recent studies have shown that HBV genotypes are closely associated with clinical manifestations and outcome in patients with acute or chronic liver diseases⁸⁻¹⁰⁾. Furthermore, recent reports have also demonstrated that the differences between genotypes B and C, and subtypes of genotype B are considered as causative agents of HCC^{5, 10-13)}. However, these data were primarily obtained from inpatients and outpatients who visited one hospital.

Approximately one million people are estimated to be HBV carriers in Japan. The majority of these HBV carriers are receiving no medical treatment or follow-up care. A small number of these HBV carriers who are HBeAg positive or have abnormal levels of serum alanine aminotransferase ALT are recognized as a high-risk group for developing CH and LC or HCC^{5, 14-16)}. However, to ensure

precise health management for all HBV carriers, it is important to clarify the differences between clinical characteristics of all HBV carriers with different genotypes.

In the present study, we clarify: 1) the prevalence of HBV genotypes in HBV carriers identified during a health-screening program in Iwate Prefecture; 2) the relationship between HBV genotypes and age; 3) the relationship between HBV genotypes and rate of positive HBeAg and changes of serum transaminase levels during long-term follow-up; and 4) the prevalence of HBV genotypes and the clinical profiles of HBV carriers complicated with hepatocellular carcinoma during a long-term follow-up.

II. Subjects and Methods

1. Subjects

From 1977 to 2004, a total of 381,601 Japanese residents (male: 172,961; female: 208,640) of Iwate Prefecture received a health screen at the institute of Iwate Healthy Science Association. Among these individuals, 6,711 residents (male: 3,576; female: 3,135) were diagnosed as HBV carriers. Using the stratified random sampling method, 661 HBV carriers (male: 343; female: 318) were recruited into samples of approximately equal age and number of individuals for a follow-up every six months or annually by the Iwate Healthy Science Association until 2004. Further 60 HBV carriers complicated with HCC during a follow-up were also recruited from the Registration System for Cancer Patients of Iwate Prefecture. However, only 30 cases with HCC were examined in this study because blood samples could not be obtained from all cases.

Demographic information for HBV carriers